Innovative biopharmaceutical company Heson Bio (688765.SH) plans to publicly issue 89.451354 million shares.

Financial news app Zhitong reports that Heyuan Biology (688765.SH) has disclosed its IPO prospectus. The company plans to issue 89.451354 million shares (excluding the number of shares issued with the over-allotment option), with no public sale of shares by shareholders. The public offering will account for 25.02% of the total share capital after this issuance. Citic Jiantou Fund- Win-Win No. 53 employees will participate in the strategic placement collective asset management plan, with the amount not exceeding 10% of the public offering, i.e. not more than 0.8945135 million shares, with a subscription amount not exceeding 240 million yuan. Haitong Innovation Investment will also participate in the strategic placement, with an initial follow-up ratio of 5% of the public offering, i.e. 4.472567 million shares. The initial inquiry date for this issuance is October 9, 2025, with the subscription date being October 14, 2025. After the issuance is completed, the company will promptly apply for the listing of its shares on the Shanghai Stock Exchange.